Bajaj Healthcare Ltd

Basis: Standalone, continuing operations where indicated, from [S&P-CIQ] cross-checked to [RES-Q4FY26] and press releases. INR M.

Income statement

Sources: [S&P-CIQ]; FY26 reconciled to [RES-Q4FY26]: revenue INR 61,103.14 lakh; PBT INR 2,892.30 lakh; net profit INR 1,576.61 lakh; basic EPS (continuing + discontinued) INR 4.98.

Company-reported (management) metrics, which differ from the vendor basis:

Source: [PR-Q4FY26]; [AR-FY26]. FY25 EBITDA is derived from the stated +9.9% growth. The company's EBITDA (INR 1,119.5 M) exceeds the vendor figure (INR 1,015 M) by about INR 105 M, most likely because management includes other income and forex gains. Readers should use the vendor basis for cross-company comparison.

Margin profile (%)

Note: FY2024 effective tax rate is shown as 0 because pre-tax income was negative (a tax credit was booked). An earlier vendor snapshot showed FY26 gross profit of INR 2,946 M (48.2%), later revised to INR 2,880 M (47.1%); the revised figure is used.

Revenue CAGR:

• FY2022–FY2026 (4-year): -2.6% p.a.

• FY2024–FY2026 (2-year, from the trough): +13.6% p.a.

Balance sheet: notes and sources

Source: [S&P-CIQ]. Total debt includes leases. FY26 net worth of INR 533.0 Cr (+14.3%) and debt/equity of 0.47x match [AR-FY26].

Cash flow: notes and sources

Source: [S&P-CIQ]. The FY26 cash acquisition of INR 81 M relates to GenRx (total consideration INR 108.5 M). FY24 OCF was flattered by a working-capital release during the revenue collapse.

Ratios

Methodology: These ratios are analyst-computed from [S&P-CIQ] data.

• ROIC = EBIT × (1 – 25% notional tax) ÷ (ending equity + ending net debt).

• Working-capital days use ending balances.

• For reference, TipRanks shows ROIC of 7.07% and ROE of 8% on a TTM basis as of late 2025.

Recent quarters (INR Cr, standalone)

Notes on the quarterly table:

• A value of 0 in the Q3/Q4 FY26 gross-profit cells and the Q3 FY26 EBITDA cell means not separately located in sources reviewed; it is not a true zero.

• Q1 FY26 gross profit of INR 69.1 Cr is from [CALL-Q1FY27].

• Q2 FY27 EBITDA of INR 32.1 Cr is derived from the company's stated +12.2% growth. One press summary instead reports INR 31 Cr (+15.8% on a base of INR 27 Cr), a discrepancy.

• Q4 FY26 net profit is INR -22.85 Cr total; the continuing-operations loss was INR -19.41 Cr.

• H1 FY27 revenue was INR 341.5 Cr (+15.1%) and PAT about INR 27.8 Cr (+21.1%) [PR-Q2FY27].

Trend commentary

Phase 1 — Commodity peak and over-extension (FY22–FY23). Revenue peaked near INR 6.8 bn in FY22, when gross margin was only 26.5%. That combination points to a high-volume, low-value mix with substantial traded and intermediate sales. Over the same period capex (INR 1.73 bn across two years, mainly Panoli and the opiate and alkaloid capacity) and working-capital build (INR 2.36 bn) were funded with debt. Total debt rose from INR 2.57 bn to INR 4.15 bn, and free cash flow was deeply negative (cumulative -INR 1.94 bn).

Phase 2 — Crisis and clean-up (FY24). Revenue fell 26.7%. Management exited the loss-making Tarapur intermediates complex, booking a INR 443 M write-down and a INR 695 M discontinued-operations loss. Interest cover dropped to 1.7x and net debt/EBITDA rose to 4.1x. India Ratings placed the A- rating on Negative outlook.

Phase 3 — Recapitalization and mix upgrade (FY25–FY26). The INR 204.97 Cr preferential issue (INR 150 Cr used for loan repayment per [MA-Q4FY26]) cut debt/equity from 1.20x to 0.47x. Gross margin steadily improved toward 47–48% as exports and formulations scaled. Underlying profit before exceptional items rose 35% in FY26. Reported earnings, however, were hit by the INR 332.5 M know-how reversal, and working capital consumed most of the operating improvement: inventory days rose to 244 and the cash conversion cycle widened to 254 days. India Ratings had explicitly said it would monitor the working-capital cycle.

Phase 4 — Early FY27. Revenue growth re-accelerated to +11.3% in Q1 and +18.9% in Q2. Gross margin held at 48.3% in both quarters, and PAT grew 15.8% and 26.9%. Press coverage of the Q2 release notes that operating cash flow diverged from net profit, implying continued working-capital absorption.

Management guidance (FY27)

• Business-mix normalization (exports and formulations) through FY27 [PR-Q1FY27]. Q2 FY27 delivered on this.

• Cenobamate commercialization from Q2 FY27, achieved Sep 2026.

• Suvorexant DCGI filing.

• Peptide facility commissioning (date conflict to resolve).

• GenRx integration after NCLT approval.

• Completion of the Tarapur sale by 31 Oct 2026.

• No numeric FY27 revenue or margin guidance located. Consensus estimates are not available (no sell-side coverage identified).

Bull case

1. Margin structure has reset higher. Gross margin has held at 47–48% for six consecutive quarters, versus 26.5% in FY22. With operating leverage, H1 FY27 PAT growth of 21% on 15% revenue growth could compound if exports and formulations keep gaining mix.

2. CNS first-mover optionality is underpriced. At about 2.1x EV/Sales and about 11.5x EV/EBITDA, the market pays little for Cenobamate (launched), Suvorexant (BE complete) and Pimavanserin. Formulations already jumped 82% in the launch quarter.

3. Balance-sheet repair plus a credit upgrade path. Debt/equity is 0.47x and vendor net debt/EBITDA is 2.07x, close to India Ratings' sub-2.0x upgrade trigger. An upgrade would cut financing costs, and the MD's insider purchase signals confidence.

Bear case

1. Cash does not follow profit. The cash conversion cycle rose to 254 days, cumulative five-year FCF is negative, and Q2 FY27 operating cash flow again lagged net profit. The equity raise may have funded inventory rather than value creation.

2. Earnings quality and guidance credibility. The INR 332.5 M know-how reversal, the FY24 collapse that followed bullish guidance, and three CFOs in about 30 months argue for a governance discount.

3. The commodity core is shrinking. Domestic API (still about 41–52% of revenue) is under Chinese price pressure and fell about 6% YoY in Q2 FY27. Large Indian pharma companies are likely to commoditize the CNS niches quickly, compressing returns that already run at about 7–8% ROIC.

Catalysts and monitorables (next 12 months)

• Q2 FY27 earnings-call transcript (19 Oct 2026): Cenobamate uptake, the peptide timeline and the rating action.

• Closure of the Orchem/Tarapur sale (target 31 Oct 2026).

• GenRx operational start and regulatory re-approvals.

• Suvorexant DCGI approval.

• Decisions on the four pending CEPs; new CDMO contracts (ANZ, South Africa).

• Q3/Q4 FY27 working-capital and operating cash flow, the single most important metric.

• Any formal credit rating revision.

• Domestic API pricing trend after the Q2 FY27 decline.

• Any recovery or settlement of the reversed Middle East know-how receivable.

Analyst verdict

Bajaj Healthcare in October 2026 is a company whose income statement has improved faster than its cash flow statement. The evidence of strategic progress is concrete:

• Gross margin has structurally reset from the mid-20s to about 48%.

• API exports have grown to nearly a third of revenue on the back of eight approved CEPs and a 30-molecule CDMO book.

• The company has achieved genuine first-in-India regulatory wins in CNS, with Cenobamate now commercial.

• A INR 205 Cr equity raise has cut leverage by more than half.

• Q2 FY27 is the cleanest quarter in two years: revenue +18.9%, PAT +26.9%, and the GenRx legal overhang removed.

Against this, three facts constrain conviction.

Working capital: A cash conversion cycle above 250 days means the business still converts too little EBITDA into free cash. Five-year cumulative FCF is negative, and ROIC sits near 7–8%, below a reasonable cost of capital.

Earnings quality: The FY26 reversal of previously recognized know-how income is a reminder that reported profits have included non-recurring and non-cash elements.

Governance and disclosure depth: Single-segment reporting, undisclosed R&D spend, unnamed CDMO counterparties and frequent CFO changes all lag what institutional investors expect. Institutional ownership below 6% reflects this.

At roughly 21x normalized earnings, 2.1x book and about 11.5x EV/EBITDA, the stock prices in a modest recovery but little specialty upside. The re-rating trigger is not more revenue growth, which is now evident. It is proof of cash conversion: two to three consecutive quarters of operating cash flow at or above PAT, inventory days falling toward 180, and the credit upgrade that India Ratings' own sensitivities imply.

Until that evidence arrives, Bajaj Healthcare is best characterized as a speculative turnaround with real pipeline optionality. Positive working-capital evidence would justify upgrading the view; another one-off charge or working-capital build would confirm the bear case.

---

Primary-document verification checklist (items to confirm against FY26 Annual Report PDF before institutional use):

1. Statutory auditor name.

2. Employee headcount (3-year trend).

3. Director and KMP remuneration.

4. R&D expenditure (5 years).

5. Independent director list and committee composition.

6. BRSR/ESG disclosures.

7. Debt maturity schedule.

8. Credit rating action referenced in Q2 FY27 coverage.

9. Peptide facility commissioning date.

10. Peer financials for §15 benchmarking.